Home » Newsletters » BioWorld Science

BioWorld Science

July 7, 2010

View Archived Issues

Safety and antitumor activity of BMS-754807 reported in phase I trial

Phase II data support use of SFP in hemodialysis-dependent patients with CKD

CGI and Genentech discover new Bruton tyrosine kinase inhibitors

CCX-354 for rheumatoid arthritis is well tolerated in healthy subjects

LAA function predicts success of catheter ablation for atrial fibrillation

ZP-2929 shows promise in preclinical models of obesity and type 2 diabetes

Novel LPA1 receptor antagonists developed at Amira

Achillion identifies new agents for hepatitis C treatment

New antibacterial agents discovered at Actelion

Ariad Pharmaceuticals reports new protein kinase inhibitors

Swedish Orphan Biovitrum and Dongbao form alliance for China and Europe

Capstone continues phase II AZX-100 trial after subset data analysis

Response Genetics launches lung genetic test to detect EML4-ALK gene variants

Sylentis completes phase Ia trial of SYL-040012 for glaucoma

Helsinn and Mundipharma sign licensing agreement for palonosetron in Asia

Nycomed receives European marketing authorization for roflumilast in COPD

EMA completes validation of Dyax's MAA for ecallantide

EC approves new indication for Orencia in rheumatoid arthritis

Cornerstone Therapeutics reacquires HMG-1 technology from MedImmune

FDA approves Shire's Daytrana for adolescents with ADHD

Genmab announces phase II data on ofatumumab in RRMS

Roche submits T-DM1 BLA to FDA for advanced HER2-positive breast cancer

FDA denies Urigen's request for end-of-phase II meeting on URG-101

NIH awards grant to Dynavax to develop universal HPV vaccine

Aquapharm and AMRI to develop marine drug-like anti-infectives

Plasma clusterin identified as biomarker for Alzheimer's disease

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 23, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 23, 2026.
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...